MedTrace Logo

A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis

NCT07417995 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-05-13

No results posted yet for this study

Summary

The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.

The main questions are:

* Do treatment responses differ according to the number of previous advanced therapies?
* Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?

Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.

Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.

Conditions

  • Psoriasis Arthritis

Interventions

DRUG

Biologic or targeted synthetic DMARD (b/tsDMARD)

This is a non-interventional observational study. Participants will receive biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as part of routine NHS clinical care, and no treatment will be assigned by the study. Participants will be categorised into cohorts according to the line of advanced therapy being initiated at study entry (first line, second/third line, fourth/fifth line, and sixth line or beyond). The study will evaluate treatment outcomes, circulating drug levels, and anti-drug antibody (ADA) status across these treatment-line groups. All treatment decisions remain at the discretion of the treating clinician.

Sponsors & Collaborators

  • University of Bath

    collaborator OTHER

  • Royal United Hospitals Bath NHS Foundation Trust

    lead OTHER

Principal Investigators

  • James Kimpton, BA (Hons) BM BCh (oxon) MRCP · Royal United Hospitals Bath NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07417995 on ClinicalTrials.gov